Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Macular Edema and Macular Degeneration Industry Expected To Reach By 2029, Starting From 2025 Levels?
The market size for macular edema and macular degeneration has shown robust expansion in recent years. This market is projected to expand from $9.65 billion in 2024 to $10.33 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this expansion has been driven by factors such as an aging population, the prevalence of diabetes, increased awareness and early diagnosis, worldwide eye health initiatives, advancements in pharmaceuticals, and patient advocacy and support.
The macular edema and macular degeneration market is anticipated to experience robust expansion in the coming years. This market is projected to reach $13.44 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.8%. Key factors driving this growth during the forecast period include the adoption of personalized medicine strategies, increasing awareness in developing markets, an emphasis on combination treatments, the integration of teleophthalmology services, and the impact of global aging populations. Notable trends expected within this period involve innovations in sustained-release drug delivery, the incorporation of gene therapies, the emergence of new imaging technologies, customized treatment strategies guided by biomarkers, the use of teleophthalmology for distant monitoring, and progress in artificial intelligence applications for diagnostics.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp
What Are The Top Growth Drivers Impacting The Macular Edema and Macular Degeneration Market Outlook?
The expanding number of individuals with diabetes is anticipated to drive the advancement of the macular edema and macular degeneration market in the future. Diabetes is a chronic medical condition defined by elevated blood sugar (glucose) levels, which damages the blood vessels in the eye, potentially leading to conditions such as macular edema and macular degeneration. For example, in June 2024, data from The National Health Service (NHS England), a UK-based publicly funded healthcare system, showed that in 2023, the number of people identified by the NHS in England with pre-diabetes grew to 3,615,330, representing an 18% increase from 3,065,825 in 2022. Furthermore, among those under 40, cases surged nearly 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Consequently, the rising diabetes population is fueling the growth of the macular edema and macular degeneration market.
What Are The Major Segments Identified In The Macular Edema and Macular Degeneration Market?
The macular edema and macular degenerationmarket covered in this report is segmented –
1) By Treatment Type: Drug Therapy; Laser Treatment
2) By Application: Macular Edema; Diabetic Macular Edema (DME); Cystoid Macular Edema (CME); Macular Degeneration; Dry age-related macular degeneration; Wet age-related macular degeneration
3) By End User: Hospitals; Clinics; Other End Users
Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections; Steroid Injections; Oral Medications; Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation; Panretinal Photocoagulation (PRP); Subthreshold Laser Therapy; MicroPulse Laser Therapy
What Trends Are Redefining The Macular Edema and Macular Degeneration Market Dynamics?
Leading companies in the macular edema and macular degeneration market are concentrating on developing innovative products, such as Vabysmo (faricimab-svoa), to enhance their profitability. Vabysmo (faricimab-svoa) is a medication utilized for managing neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). For example, in January 2022, Genentech Inc., a biotechnology corporation based in the US, received approval for Vabysmo (faricimab-svoa) from the Food and Drug Administration. This substance is a bispecific antibody designed to target vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), making it the first bispecific monoclonal antibody for both conditions. Faricimab holds the potential to become a highly successful medication for treating nAMD and DME, and its approval by the FDA and EU represents a significant accomplishment for Genentech and Roche.
Which Major Firms Are Strengthening Their Position In The Macular Edema and Macular Degeneration Industry?
Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited
Download The Full Report For Exclusive Market Findings:
What Regional Growth Trends Are Shaping The Macular Edema and Macular Degeneration Market Outlook?
North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Macular Edema and Macular Degeneration Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp
Browse Through More Reports Similar to the Global Macular Edema and Macular Degeneration Market 2025, By The Business Research Company
Age Related Macular Degeneration Global Market Report 2025
Macular Degeneration Treatment Global Market Report 2025
Alopecia Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/alopecia-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model